Alimera Sciences Stock Forecast, Price & News

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Alimera Sciences in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Alimera Sciences stock.
View analyst ratings for Alimera Sciences or view top-rated stocks.

Wall Street analysts have given Alimera Sciences a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Alimera Sciences wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Alimera Sciences is scheduled to release its next quarterly earnings announcement on Wednesday, August 4th 2021.
View our earnings forecast for Alimera Sciences.

Alimera Sciences, Inc. (NASDAQ:ALIM) announced its quarterly earnings data on Tuesday, April, 27th. The biopharmaceutical company reported ($0.63) EPS for the quarter, missing analysts' consensus estimates of ($0.54) by $0.09. The biopharmaceutical company had revenue of $11.21 million for the quarter, compared to the consensus estimate of $11.60 million.
View Alimera Sciences' earnings history.

Alimera Sciences' stock was trading at $5.24 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, ALIM stock has increased by 72.7% and is now trading at $9.05.
View which stocks have been most impacted by COVID-19.

Shares of Alimera Sciences reverse split on Friday, November 15th 2019. The 1-15 reverse split was announced on Thursday, November 7th 2019. The number of shares owned by shareholders was adjusted after the market closes on Thursday, November 14th 2019. An investor that had 100 shares of Alimera Sciences stock prior to the reverse split would have 7 shares after the split.

2 analysts have issued 1-year price targets for Alimera Sciences' shares. Their forecasts range from $16.00 to $16.50. On average, they anticipate Alimera Sciences' stock price to reach $16.25 in the next year. This suggests a possible upside of 79.6% from the stock's current price.
View analysts' price targets for Alimera Sciences or view top-rated stocks among Wall Street analysts.

2 employees have rated Alimera Sciences CEO Rick Eiswirth on Glassdoor.com. Rick Eiswirth has an approval rating of 100% among Alimera Sciences' employees. This puts Rick Eiswirth in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Some companies that are related to Alimera Sciences include Corbus Pharmaceuticals (CRBP), Taiwan Liposome (TLC), Spruce Biosciences (SPRB), Chiasma (CHMA), Hookipa Pharma (HOOK), Marker Therapeutics (MRKR), BioVie (BIVI), BCTG Acquisition (BCTG), AVEO Pharmaceuticals (AVEO), Chemomab Therapeutics (CMMB), Jaguar Health (JAGX), Synlogic (SYBX), Zynerba Pharmaceuticals (ZYNE), Tricida (TCDA) and Tyme Technologies (TYME).
View all of ALIM's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Alimera Sciences investors own include EyePoint Pharmaceuticals (EYPT), OPKO Health (OPK), VBI Vaccines (VBIV), Aldeyra Therapeutics (ALDX), Advanced Micro Devices (AMD), Amarin (AMRN), AngloGold Ashanti (AU), SSR Mining (SSRM), ADMA Biologics (ADMA) and Cellectar Biosciences (CLRB).

Alimera Sciences trades on the NASDAQ under the ticker symbol "ALIM."

Alimera Sciences' stock is owned by a variety of retail and institutional investors. Top institutional investors include Morgan Stanley (6.15%), Renaissance Technologies LLC (2.10%), Knott David M (0.84%), Cooper Creek Partners Management LLC (0.55%), Diametric Capital LP (0.38%) and Geode Capital Management LLC (0.32%). Company insiders that own Alimera Sciences stock include James R Largent, John Philip Jones, John Snisarenko, Philip Ashman and Richard S Eiswirth Jr.
View institutional ownership trends for Alimera Sciences.

ALIM stock was sold by a variety of institutional investors in the last quarter, including Knott David M, and Renaissance Technologies LLC.
View insider buying and selling activity for Alimera Sciences or view top insider-selling stocks.

ALIM stock was purchased by a variety of institutional investors in the last quarter, including Cooper Creek Partners Management LLC, Diametric Capital LP, Perritt Capital Management Inc., PDT Partners LLC, Citadel Advisors LLC, Citadel Advisors LLC, Geode Capital Management LLC, and Acadian Asset Management LLC. Company insiders that have bought Alimera Sciences stock in the last two years include James R Largent, John Philip Jones, John Snisarenko, and Richard S Eiswirth Jr.
View insider buying and selling activity for Alimera Sciences or or view top insider-buying stocks.

Shares of ALIM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ALIM stock can currently be purchased for approximately $9.05.

Alimera Sciences has a market capitalization of $62.59 million and generates $50.82 million in revenue each year. The biopharmaceutical company earns $-5,340,000.00 in net income (profit) each year or ($1.04) on an earnings per share basis.

Alimera Sciences employs 130 workers across the globe.

The official website for Alimera Sciences is www.alimerasciences.com.

Alimera Sciences is headquartered at 6120 WINDWARD PARKWAY STE 290, ALPHARETTA GA, 30005.

Alimera Sciences' mailing address is 6120 WINDWARD PARKWAY STE 290, ALPHARETTA GA, 30005. The biopharmaceutical company can be reached via phone at 678-990-5740 or via email at [email protected]